Table 2 Comparison of baseline characteristics between “IM C_min ≤ 1100 ng/ml” and “IM C_min > 1100 ng/ml”

Demographic information

Age at diagnosis (years)

56 (49–65)

55 (49–62)

58 (50–66)

0.006^a

Age at blood sampling (years)

61 (53–68)

59 (53–67)

62 (54–68)

0.004^a

Gender

 < 0.001^b

Male

526 (59.10%)

212 (76.26%)

314 (51.31%)

Female

364 (40.90%)

66 (23.74%)

298 (48.69%)

Treatment information

Surgical procedure

0.786^b

Gastrectomy

165 (18.54%)

53 (19.06%)

112 (18.30%)

Non-gastric operation

725 (81.46%)

225 (80.94%)

500 (81.70%)

Daily IM dose

0.010^b

 ≤ 200mg/d

28 (3.15%)

17 (6.12%)

11 (1.80%)

300mg/d

89 (10.00%)

27 (9.71%)

62 (10.13%)

400mg/d

679 (76.29%)

204 (73.38%)

475 (77.61%)

500mg/d

54 (6.07%)

20 (7.19%)

34 (5.56%)

 ≥ 600mg/d

40 (4.49%)

10 (3.60%)

30 (4.90%)

Clinical information

DOG-1

0.788^b

Positive

859 (96.52%)

269 (96.76%)

590 (96.41%)

Negative

31 (3.48%)

9 (3.24%)

22 (3.59%)

CD117

0.639^b

Positive

878 (98.65%)

275 (98.92%)

603 (98.53%)

Negative

12 (1.35%)

3 (1.08%)

9 (1.47%)

CD34

0.138^b

Positive

795 (89.33%)

242 (87.05%)

553 (90.36%)

Negative

95 (10.67%)

36 (12.95%)

59 (9.64%)

Primary tumor site

0.163^b

Stomach

293 (32.92%)

91 (32.73%)

202 (33.01%)

Small intestine

352 (39.55%)

121 (43.53%)

231 (37.75%)

Colorectum

74 (8.31%)

16 (5.76%)

58 (9.48%)

Other

171 (19.21%)

50 (17.99%)

121 (19.77%)

Metastatic site

0.024^b

Liver

405 (45.51%)

142 (51.08%)

263 (42.97%)

Non-liver

485 (54.49%)

136 (48.92%)

349 (57.03%)

Laboratory indicators

WBC (*10⁹/L)

4.32 (3.47–5.39)

4.33 (3.45–5.44)

4.31 (3.47–5.38)

0.812^a

PLT (*10⁹/L)

173 (136–220)

171 (129–217)

176 (137–220)

0.355^a

NEU%

61.25 (53.30–68.90)

59.75 (51.73–66.70)

62.30 (54.00–70.18)

 < 0.001^a

RBC (*10¹²/L)

3.65 (3.27–4.04)

3.86 (3.52–4.30)

3.54 (3.18–3.91)

 < 0.001^a

HB (g/L)

115 (103–126)

121 (109–134)

112 (101–123)

 < 0.001^a

LYM%

27.30 (20.38–35.10)

29.65 (22.23–37.03)

26.50 (19.60–34.50)

 < 0.001^a

ALT (U/L)

16 (12–22)

18 (13–26)

15 (12–21)

 < 0.001^a

AST (U/L)

23 (19–28)

24 (19–29)

23 (19–27)

0.051^a

TBIL (umol/L)

8.70 (6.60–11.70)

8.90 (6.88–12.13)

8.50 (6.40–11.30)

0.026^a

DBIL (umol/L)

3.95 (3.20–5.10)

4.00 (3.30–5.40)

3.90 (3.10–5.00)

0.065^a

IBIL (umol/L)

4.60 (3.20–6.40)

4.65 (3.58–6.73)

4.50 (3.10–6.30)

0.026^a

GGT (U/L)

17 (12–27)

19 (14–31)

16 (11–25)

 < 0.001^a

AKP (U/L)

69 (57–85)

70 (57–87)

69 (57–84)

0.774^a

Cr (umol/L)

82 (71–97)

85 (75–96)

81 (69–98)

0.038^a

BUN (mmol/L)

5.40 (4.40–6.40)

5.60 (4.50–6.60)

5.30 (4.20–6.30)

0.010^a

eGFR (ml/min)

85.35 (69.40–96.15)

86.55 (73.55–98.40)

85.00 (68.20–95.35)

0.033^a